
Terlipressin Acetate
CAS No. 1884420-36-3
Terlipressin Acetate ( Terlipressin diacetate anhydrous | Terlipressin acetate anhydrous )
产品货号. M23860 CAS No. 1884420-36-3
特利加压素是一种高选择性加压素 V1 受体激动剂,可抑制缺氧和葡萄糖剥夺/再氧合 (OGD/R) 引起的肠上皮细胞损伤 (IEC-6)。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥332 | 有现货 |
![]() ![]() |
10MG | ¥454 | 有现货 |
![]() ![]() |
25MG | ¥851 | 有现货 |
![]() ![]() |
50MG | ¥1118 | 有现货 |
![]() ![]() |
100MG | ¥1766 | 有现货 |
![]() ![]() |
200MG | ¥2649 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Terlipressin Acetate
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述特利加压素是一种高选择性加压素 V1 受体激动剂,可抑制缺氧和葡萄糖剥夺/再氧合 (OGD/R) 引起的肠上皮细胞损伤 (IEC-6)。
-
产品描述Terlipressin, a highly selective vasopressin V1 receptor agonist, on oxygen and glucose deprivation/re-oxygenation (OGD/R)-induced damage in intestinal epithelial cells (IEC-6).Terlipressin acetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin acetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research.
-
体外实验Cell Proliferation Assay Cell Line:IEC-6 cells induced by oxygen and glucose deprivation/re-oxygenation (OGD/R)Concentration:25 nM Incubation Time:24 hours, 48 hours, 72 hours Result:Significantly increased the proliferation of IEC-6 cells.
-
体内实验——
-
同义词Terlipressin diacetate anhydrous | Terlipressin acetate anhydrous
-
通路GPCR/G Protein
-
靶点Vasopressin Receptor
-
受体vasopressin V1
-
研究领域——
-
适应症——
化学信息
-
CAS Number1884420-36-3
-
分子量1347.5
-
分子式C56H82N16O19S2
-
纯度>98% (HPLC)
-
溶解度DMSO:95mg/mL (70.50mM)
-
SMILESO=C([C@H](CSSC[C@@H](C(N[C@H](C1=O)CC2=CC=C(O)C=C2)=O)NC(CNC(CNC(CN)=O)=O)=O)NC([C@@H](NC([C@@H](NC([C@](N1)([H])CC3=CC=CC=C3)=O)CCC(N)=O)=O)CC(N)=O)=O)N(CCC4)[C@@H]4C(N[C@@H](CCCCN)C(NCC(N)=O)=O)=O.CC(O)=O.CC(O)=O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Liu ZM, Zhang XY, Chen J, Shen JT, Jiang ZY, Guan XD. Terlipressin protects intestinal epithelial cells against oxygen-glucose deprivation/re-oxygenation injury via the phosphatidylinositol 3-kinase pathway. Exp Ther Med. 2017;14(1):260-266. doi:10.3892/etm.2017.4502
产品手册




关联产品
-
OPC-51803
OPC-51803 is an orally available nonapeptidylpressor (AVP) V(2) receptor selective agonist for the treatment of urinary incontinence and nocturia.
-
Conivaptan
一种有效的、选择性的非肽加压素 V1A 和 V2 受体拮抗剂,Ki 分别为 0.48 nM 和 3.04 nM;对 OT 受体的效力较低,对 V1B 受体没有影响。
-
Desmopressin
去氨加压素 (DDAVP) 是抗利尿激素精氨酸加压素的合成类似物。加压素受体 去氨加压素的抗利尿特性导致其用于治疗多尿性疾病,包括原发性夜间遗尿症、夜尿症和尿崩症。